| 000 | 01603 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250516060124.0 | ||
| 264 | 0 | _c20120201 | |
| 008 | 201202s 0 0 eng d | ||
| 022 | _a2146-8427 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDogu, Figen | |
| 245 | 0 | 0 |
_aCD40 ligand deficiency with grade III liver fibrosis, transplanted by a treosulphan-based conditioning regimen. _h[electronic resource] |
| 260 |
_bExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation _cOct 2011 |
||
| 300 |
_a349-52 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aBiopsy |
| 650 | 0 | 4 |
_aBone Marrow Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aBusulfan _xadverse effects |
| 650 | 0 | 4 |
_aCD40 Ligand _xdeficiency |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 | _aHistocompatibility Testing |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyper-IgM Immunodeficiency Syndrome, Type 1 _ximmunology |
| 650 | 0 | 4 |
_aLiver Cirrhosis _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xadverse effects |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aCipe, Funda Erol | |
| 700 | 1 | _aReisli, Ismail | |
| 700 | 1 | _aErden, Esra | |
| 700 | 1 | _aIkinciogullari, Aydan | |
| 773 | 0 |
_tExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation _gvol. 9 _gno. 5 _gp. 349-52 |
|
| 999 |
_c21203544 _d21203544 |
||